Status:
TERMINATED
Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids
Lead Sponsor:
Augusta University
Collaborating Sponsors:
Eli Lilly and Company
Medical Service Line ABRC
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
This research study helps to demonstrate that adding vitamins and fats (nutritional supplements) to a diet will help reduce body weight and improve the lipid profile. This will be done by examining th...
Detailed Description
To demonstrate that supplementation of antioxidants and omega-3 fatty acids will improve clinical outcome including cognitive performance in olanzapine treated patients.
Eligibility Criteria
Inclusion
- Age 18 to 55
- VA outpatient
- Diagnosis of schizophrenia by DSM-IV criteria
- Active treatment with olanzapine
- Medically healthy
Exclusion
- Diagnosis of MR
- MMSE score of \< 26
- Not on a stable dose of olanzapine
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00211562
Start Date
October 1 2005
Last Update
October 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center
Augusta, Georgia, United States, 30904